Pulmatrix, Inc.
$1.34
▼
-0.76%
2026-04-21 09:00:00
www.pulmatrix.com
NCM: PULM
Explore Pulmatrix, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.91 M
Current Price
$1.34
52W High / Low
$9.37 / $1.16
Stock P/E
—
Book Value
$1.04
Dividend Yield
—
ROCE
-135.67%
ROE
-80.93%
Face Value
—
EPS
$-1.41
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
1.97
Debt / Equity
—
Current Ratio
12.55
Quick Ratio
12.55
Forward P/E
-0.27
Price / Sales
—
Enterprise Value
$0.29 M
EV / EBITDA
-0.06
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 2. | Indaptus Therapeutics, Inc. | $3.61 | — | $7.74 M | — | -629.32% | -5.88% | $19.91 / $1.51 | $1.45 |
| 3. | Psyence Biomedical Ltd. | $11.3 | 30.05 | $7.77 M | — | -54.49% | -74.29% | $468.38 / $1.92 | $39.62 |
| 4. | Actinium Pharmaceuticals, Inc. | $1.44 | — | $42.98 M | — | -82.74% | -1.67% | $1.95 / $0.95 | $0.25 |
| 5. | Halozyme Therapeutics, Inc. | $68.8 | 26.89 | $8.18 B | — | 34.18% | 1.54% | $82.22 / $47.5 | $0.41 |
| 6. | Damora Therapeutics, Inc. | $26.43 | — | $1.6 B | — | -87.69% | -1.64% | $29.22 / $16.5 | $-110.11 |
| 7. | NewAmsterdam Pharma Company N.V. | $33.82 | — | $3.89 B | — | -33.02% | -28.29% | $42 / $15.82 | $5.97 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -0.91 M | -0.87 M | -1.55 M | -1.85 M | -1.95 M | — |
| Net Profit | -0.93 M | -0.88 M | -1.55 M | -1.81 M | -1.99 M | — |
| EPS in Rs | -0.25 | -0.24 | -0.42 | -0.5 | -0.54 | -0.71 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 7.81 M | 7.3 M | 6.07 M |
| Operating Profit | -5.17 M | -7.14 M | -14.74 M | -18.95 M |
| Net Profit | -5.16 M | -9.56 M | -14.12 M | -18.84 M |
| EPS in Rs | -1.41 | -2.62 | -3.87 | -5.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.14 M | 9.94 M | 33.96 M | 40.95 M |
| Total Liabilities | 0.33 M | 1 M | 15.96 M | 9.84 M |
| Equity | 3.81 M | 8.95 M | 18 M | 31.11 M |
| Current Assets | 4.13 M | 9.92 M | 20.84 M | 38.15 M |
| Current Liabilities | 0.33 M | 0.93 M | 3.91 M | 5.02 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.43 M | -10.72 M | -15.98 M | -19.36 M |
| Investing CF | 0 M | -0.4 M | -0.68 M | -0.09 M |
| Financing CF | — | 0 M | 0.05 M | 1.23 M |
| Free CF | -5.43 M | -11.11 M | -16.66 M | -19.44 M |
| Capex | — | -0.4 M | -0.68 M | -0.09 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 6.96% | 20.21% | — | — |
| Earnings Growth % | 32.31% | 25.03% | — | — |
| Profit Margin % | -122.46% | -193.49% | -310.26% | — |
| Operating Margin % | -91.53% | -201.97% | -312.09% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -85.96% | -181.76% | -286.64% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-03-01 | 1:0.05 |